Login
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc.

armatapharma.com

What Do They Do?

Develops phage-based drug candidates for patients with antibiotic-resistant lung and bloodstream infections.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $173.8M in FY2025.

Operating income, FY2025
−747% of revenue
▲ +14% (Loss) vs FY2024 (−$42.4M, −820%)
Net income, FY2025
−3544% of revenue
▼ −819% (Loss) vs FY2024 (−$18.9M, −366%)
Free cash flow, FY2025
−536% of revenue
▲ +33% (Loss) vs FY2024 (−$39.4M, −762%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ Turned profitable
vs −$26.7M in Q3 FY2025
  • Jul 17, 2026 David House appointed chief financial officer

Growing. Revenue grew 10% in 4 years, from $4.5M in FY2021 to $4.9M in FY2025, about 2% a year.

Acute lung infections The latest report adds a preclinical program for acute Pseudomonas lung infections; the older report described a chronic lung program and a complicated bloodstream-infection program.

Who Do They Compete With?

Competes with BiomX, Adaptive Phage Therapeutics, Intralytix, Locus Biosciences, and TechnoPhage

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support